Number of eligible people: CDEC reviewed the uncertainty in the number of clients with moderately intense to severe hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some patients who will be classified as owning mild or average disease may have a significant bleeding https://valeriusv367tuv0.bcbloggers.com/profile